Ono Hidetaka A, Suwa Hirokazu, Minami Yuta, Nojiri Kazunori, Yoshida Kenichi, Masui Hidenobu, Nagahori Kaoru
Dept. of Surgery, Yokosuka Kyosai Hospital.
Gan To Kagaku Ryoho. 2023 Dec;50(13):1892-1894.
A 25-year-old male received palliative total gastrectomy plus D1 dissection plus Roux-en-Y reconstruction for hemorrhagic gastric cancer with left Virchow lymph node metastasis in 2013. The final diagnosis was Type 2, pT4a(se), pap>tub2 >hepatoid adenocarcinoma, pN3b, sM1, fStage Ⅳ. Because AFP was as high as 11,000 ng/mL, he was diagnosed with AFP-producing gastric cancer and started S-1 plus CDDP therapy. Left adrenal gland metastasis and #106pre, #16b1int lymph node metastasis were observed after 9 courses, and the therapy was changed to irinotecan plus CDDP therapy. After 17 courses, the patient was diagnosed with CR, and the drug was discontinued. Recurrence of the left adrenal gland and an increase in AFP were confirmed by CT after 8 months of suspension, and the drug was resumed. After 8 courses of resumption, PET-CT showed mediastinal and #16b1lat lymph node metastasis and changed to weekly PTX plus Ram therapy. After 2 courses, enlargement of lymph nodes and elevation of AFP was observed, and CapeOX therapy was changed. Diagnosis of left adrenal metastasis recurrence by PET-CT after 21 courses. Nivolumab was used, and radiotherapy(total 39 Gy)was performed locally. After the continuation of nivolumab for 3 years, no findings of recurrent metastasis were observed on imaging, and it was judged as CR, and nivolumab was terminated. As of June 2023, he is alive without recurrence. AFP-producing gastric cancer in the young is rare, and no cases with Virchow metastasis or para-aortic lymph node metastasis have been reported. We report a case of long-term survival in which CR was obtained with combined modality therapy.
一名25岁男性于2013年因出血性胃癌伴左锁骨上淋巴结转移接受了姑息性全胃切除术加D1清扫术及Roux-en-Y重建术。最终诊断为2型,pT4a(se),乳头状>管状2型>肝样腺癌,pN3b,sM1,f分期Ⅳ期。由于甲胎蛋白高达11,000 ng/mL,他被诊断为甲胎蛋白产生型胃癌,并开始接受S-1加顺铂治疗。9个疗程后观察到左肾上腺转移及#106前、#16b1内淋巴结转移,治疗改为伊立替康加顺铂治疗。17个疗程后,患者被诊断为完全缓解,药物停用。停药8个月后CT证实左肾上腺复发且甲胎蛋白升高,遂恢复用药。恢复用药8个疗程后,PET-CT显示纵隔及#16b1外侧淋巴结转移,改为每周紫杉醇加雷莫西尤单抗治疗。2个疗程后,观察到淋巴结肿大及甲胎蛋白升高,改为CapeOX治疗。21个疗程后PET-CT诊断为左肾上腺转移复发。使用纳武利尤单抗,并局部进行放疗(总计39 Gy)。纳武利尤单抗持续使用3年后,影像学检查未发现复发转移迹象,判定为完全缓解,纳武利尤单抗停药。截至2023年6月,他存活且无复发。年轻患者中甲胎蛋白产生型胃癌罕见,尚无伴有锁骨上转移或主动脉旁淋巴结转移的病例报道。我们报告了一例通过综合治疗获得完全缓解并长期生存的病例。